Raymond James Downgrades PTC Therapeutics to Underperform
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Danielle Brill has downgraded PTC Therapeutics (NASDAQ:PTCT) from Outperform to Underperform.
September 18, 2023 | 8:14 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
PTC Therapeutics has been downgraded by Raymond James from Outperform to Underperform.
Analyst ratings often have a direct impact on a company's stock price. A downgrade from Outperform to Underperform suggests that the analyst believes the company's stock will underperform the market or its sector in the near future. This could lead to a decrease in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100